Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bracco SPA

www.bracco.com

Latest From Bracco SPA

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence

Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation

The latest drug development news and highlights from our FDA Performance Tracker.

United States BioPharmaceutical

EnteroMedics Appoints CEO

EnteroMedics Inc., a company developing medical devices, has appointed Dan Gladney president and CEO – effective Nov. 16, 2015. Gladney has also been appointed to the company's board. Current president, CEO and chair of EnteroMedics, Mark Knudson, will remain its executive chair until the beginning of 2016, when he will become non-executive chair of the company's board. Most recently Gladney was director and CEO of Lanx Inc., a medical device company, which was later acquired by Biomet Inc. Prior to Lanx, Gladney was healthcare operating partner at Norwest Equity Partners and prior to this, he was president and CEO of various companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group.

Companies

Apricus Bio's Vitaros rejected in Switzerland due to 'quality issues'

The Swiss medical agency Swissmedic has recommended against approval of San Diego-based Apricus Biosciences' erectile dysfunction product Vitaros (alprostadil) due to "quality related issues" issues with the drug's shelf life. This is in spite of the fact that the agency was happy with the company's data.

Sweden
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register